ANALOG Pharma

What ANALOG Pharma does

Analog Pharma Inc. is a privately held US generic pharmaceutical company headquartered in Princeton, New Jersey, and a member of the Quebec-based Duchesnay Pharmaceutical Group. The company develops, manufactures, and commercializes high-quality generic and authorized generic medications, with a focus on orphan drugs and treatments for rare diseases, while pursuing reshoring and nearshoring strategies to ensure continuous product access. Its core commercial products are Nitisinone capsules (2, 5, 10, and 20 mg), an AB-rated generic equivalent of Swedish Orphan Biovitrum's Orfadin indicated for hereditary tyrosinemia type 1 (HT-1), distinguished by a room temperature stable formulation developed in partnership with Dipharma S.A. that eliminates the cold-chain requirements of the reference product; and Doxylamine succinate / pyridoxine hydrochloride delayed-release tablets for nausea and vomiting in pregnancy.

Analog Pharma distributes its products through specialty pharmacies and wholesalers in the US, with patient assistance programs offering Nitisinone at $0 per prescription for eligible patients. In January 2024 the company established Analog Pharma Canada as a subsidiary, and in September 2025 launched PrALOG-Doxylamine/Pyridoxine, its first Canadian product and a generic version of Duchesnay's maternal health brand PrDiclectin, manufactured in Quebec. The company operates with 1-10 employees and is privately held, generating revenue through standard generic pharmaceutical sales with pricing negotiated via specialty distribution channels rather than publicly disclosed. As of late 2021, the entire Duchesnay Pharmaceutical Group, including Analog Pharma, is owned by the senior management team led by Eric Gervais following a buyout from the Boivin family, supported by BDC.

Name

ANALOG Pharma

Legal name

Analog Pharma Inc.

Website

https://analogpharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Analog Pharma is a privately held US generic pharmaceutical company, member of Duchesnay Pharmaceutical Group, that develops and commercializes generic and authorized generic medications for rare diseases (notably Nitisinone for HT-1) and maternal health, distributed via specialty pharmacies and wholesalers in the US and Canada.

Ownership category

akta.pro rank

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Generic Pharmaceutical Sales: Analog Pharma generates revenue through the sale of FDA-approved generic medications. Products are distributed through specialty pharmacies and wholesalers, with pricing that provides affordable access to patients. The company offers products like Nitisinone capsules for as little as $0 per prescription for eligible patients through patient assistance programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Analog Pharma develops, manufactures, and distributes FDA-approved generic pharmaceutical products — chiefly orphan drugs and authorized generics — including room-temperature stable Nitisinone capsules (for hereditary tyrosinemia type-1) and Doxylamine succinate/Pyridoxine delayed-release tablets (for nausea and vomiting in pregnancy). Products are sold via specialty pharmacies and wholesalers under FDA Abbreviated New Drug Application (ANDA) approvals, with patient-assistance pricing for eligible patients.

Product overview

Analog Pharma is a generic pharmaceutical company specializing in developing and producing high-quality generic medications for patients with rare diseases and other illnesses. The company's product portfolio includes Doxylamine succinate & pyridoxine hydrochloride (a delayed-release antihistamine plus Vitamin B6 tablet for nausea in pregnancy), Nitisinone Capsules (available in 2mg, 5mg, 10mg, and 20mg strengths for hereditary tyrosinemia type 1), and PrALOG-Doxylamine/PyridoxineTM (a Canadian-market generic version of PrDiclectin®). The company focuses on orphan and rare disease medications while ensuring widest possible access to affordable treatments.

Differentiator

Problem solved

Functional benefit

Brands

• PrALOG-Doxylamine/Pyridoxine: Generic version of DPG's flagship nausea and vomiting treatment PrDiclectin for pregnant women, launched in Canada in September 2025.

Products and services

• Nitisinone Capsules (2, 5, 10, 20 mg) Room-temperature stable hydroxy-phenylpyruvate dioxygenase inhibitor capsules available in 2, 5, 10, and 20 mg strengths for the treatment of hereditary tyrosinemia type 1 (HT-1) in adult and pediatric patients, in combination with dietary restriction of tyrosine and phenylalanine. AB-rated generic equivalent of Swedish Orphan Biovitrum's Orfadin®. Stable at room temperature for 2-3 years, eliminating refrigeration.
• Doxylamine succinate & pyridoxine hydrochloride delayed-release tablets Delayed-release tablet combining an antihistamine (doxylamine succinate) with Vitamin B6 (pyridoxine hydrochloride), indicated for the treatment of nausea and vomiting in pregnancy. AB-rated generic therapeutic equivalent, certified Kosher, Kosher for Passover, and Halal.
• PrALOG-Doxylamine/Pyridoxine™ (Canada) Canadian-market generic version of Duchesnay Pharmaceutical Group's flagship nausea and vomiting treatment PrDiclectin® for pregnant women. Manufactured in Quebec and represents Analog Pharma Canada's entry into the Canadian pharmaceutical market.

Quantifiable outcome

• Nitisinone available at $0 per prescription for eligible patients through patient assistance programs
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Dipharma S.A.coreStrategic or Co-development Partner · 21 June 2022Analog Pharma and Dipharma S.A. maintain a strategic partnership for the development and commercialization of generic nitisinone capsules. Dipharma, a Swiss specialty pharmaceutical company, developed the room temperature stable nitisinone formulation and holds the ANDA approval. Analog Pharma serves as the US distribution partner, bringing the product to American HT-1 patients. The partnership has resulted in FDA approvals for nitisinone capsules in 2, 5, 10, and 20 mg strengths. Dipharma's nitisinone was first approved and launched in Europe before expanding to the US through Analog Pharma.
• Duchesnay Pharmaceutical GroupcoreOthersAnalog Pharma is a member of Duchesnay Pharmaceutical Group, a Quebec-based multinational pharmaceutical group headquartered in Blainville, Quebec. The Group consists of five pharmaceutical companies: Duchesnay and Duchesnay USA (women's health), Médunik Canada and Medunik USA (rare diseases), and Analog Pharma (American generic drugs). Analog Pharma specializes in authorized generics and orphan drugs. The Group operates a state-of-the-art manufacturing facility in Quebec and exports to 50+ countries. In November 2021, the senior management team acquired ownership of the Group from Pierre Boivin and family.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Apotex: Apotex is a Canadian-headquartered generic pharmaceutical manufacturer producing finished dosage forms for global markets, with deep Canadian retail/pharmacy relationships. It is comparable to Analog in category (generic finished dosage forms), manufacturing geography (Canada), and competitive overlap in the Canadian market where Analog Canada just launched.
• Amneal Pharmaceuticals: Amneal is a US-focused generic and specialty pharmaceutical manufacturer with a meaningful specialty/affordable-medicines segment serving US patients through specialty distribution. Like Analog, it competes in the US generics market with FDA-approved ANDA products and pursues a portfolio approach to affordable medicines.
• Swedish Orphan Biovitrum (Sobi): Sobi is a global specialty biopharmaceutical company focused on rare diseases and the originator of Orfadin (nitisinone), which is Analog's direct generic competitor. It is the most directly comparable peer because Analog's core product is the bioequivalent generic to Orfadin and competes head-to-head for the same HT-1 patients.
• Prasco Laboratories: Prasco is a US specialty pharmaceutical company specializing in authorized generics — branded products marketed under their generic names — distributed through the same specialty-pharmacy and wholesaler channels. It is comparable to Analog because both companies focus on the authorized-generic niche, often substituting for established brand-name rare-disease products through the same US distribution architecture.
• Upsher-Smith Laboratories: Upsher-Smith is a US-based specialty generic pharmaceutical company focused on small-molecule generics across therapeutic categories, distributing primarily through wholesalers and pharmacies. It is comparable to Analog as a similarly sized US-focused generic specialist with comparable commercial and distribution mechanics.
• Medunik USA: Medunik USA is a US specialty pharmaceutical company focused on orphan drugs and rare diseases and is a sibling company within the Duchesnay Pharmaceutical Group alongside Analog Pharma. It is the most directly comparable peer in mission (US-rare-disease specialty pharma) and operational footprint, though it serves a different therapeutic mix.

Broad incumbents

• Sandoz: Sandoz is the world's largest generic pharmaceutical company (spun out of Novartis in 2023) producing a broad portfolio of generic and biosimilar medicines across many therapeutic areas including rare diseases. It is comparable to Analog Pharma as a broad incumbent in the same generic-pharma category, though with vastly greater scale and a much wider product range.
• Viatris: Viatris is a global healthcare company formed from the merger of Mylan and Upjohn that produces generic, brand, and biosimilar medicines across therapeutic areas. It is comparable to Analog as a broad incumbent competitor in the US generic pharmaceutical market, including in specialty/rare-disease generics.
• Teva Pharmaceutical Industries: Teva is the largest global generic pharmaceutical manufacturer and operates a dedicated specialty medicines business that includes rare-disease products. It is comparable to Analog as the broadest incumbent in generic pharmaceuticals, with overlapping competitive pressure on price, distribution, and ANDA strategy in the US market.

Emerging players

• Dipharma S.A. Dipharma is a Swiss specialty pharmaceutical company developing and supplying generic and contract-manufactured APIs and finished products, including the room-temperature-stable nitisinone formulation that Analog commercializes in the US. It is comparable as a partner/competitor in the same ANDA-based generic-pharma category, with overlapping capabilities in specialty generics and orphan drugs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/analog-pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ANALOG Pharma